Stock CRNO B CERENO SCIENTIFIC AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Equities

CRNO B

SE0008241558

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2023-06-19 pm EDT 		5-day change 1st Jan Change
0.521 SEK -7.13% Intraday chart for Cereno Scientific AB (publ) +7.98% -76.90%
Apr. 16 Cereno Scientific AB Approves Election of New Directors CI
Apr. 11 Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate MT

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 81.85 534.7 310.1 1,070 1,107 - -
Enterprise Value (EV) 1 81.85 534.7 310.1 1,029 1,110 1,252 1,107
P/E ratio -9.69 x - -11.9 x -21.8 x -20.7 x -23.2 x -
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - -35.7 x -11.3 x -23.1 x -14.8 x -30.7 x -30.2 x
EV / FCF - - -4.07 x -27.9 x -14.8 x - -
FCF Yield - - -24.6% -3.59% -6.76% - -
Price to Book - 3.14 x - - - - -
Nbr of stocks (in thousands) 40,219 105,262 137,515 233,775 280,980 - -
Reference price 2 2.035 5.080 2.255 4.575 3.940 3.940 3.940
Announcement Date 2/25/21 2/9/22 2/22/23 2/21/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - -
EBITDA 1 - -14.99 -27.51 -44.64 -75 -40.79 -36.7
EBIT 1 - -15.01 -27.52 -44.65 -75 -40.79 -36.7
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 - -16.25 -27.65 -48.11 -51.2 -42.65 -36.7
Net income 1 -16.02 -16.25 -27.65 -48.11 -75 -42.67 -36.7
Net margin - - - - - - -
EPS 2 -0.2100 - -0.1900 -0.2100 -0.1900 -0.1700 -
Free Cash Flow 1 - - -76.15 -36.92 -75 - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 2/25/21 2/9/22 2/22/23 2/21/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 3 145 -
Net Cash position 1 - - - 40.5 - - -
Leverage (Debt/EBITDA) - - - - -0.04 x -3.56 x -
Free Cash Flow 1 - - -76.2 -36.9 -75 - -
ROE (net income / shareholders' equity) - - -14.9% -19.8% -46% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - 1.620 - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 2/25/21 2/9/22 2/22/23 2/21/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
GENMAB A/S Stock Genmab A/S
-8.14% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CRNO B Stock
  4. CRNO B Stock
  5. Financials Cereno Scientific AB (publ)